Skip to main content Back to Top
Advertisement

3/24/2020

Ropivacaine Injection

Products Affected - Description

    • Naropin injection, Fresenius Kabi, 2 mg/mL, 100 mL infusion bottle, 1 count, NDC 63323-0285-65
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 200 mL infusion bottle, 1 count, NDC 63323-0285-64
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 30 mL Steripak plastic ampule, 5 count, NDC 63323-0286-31
    • Ropivacaine injection, AuroMedics, 10 mg/mL, 10 mL vial, 25 count, NDC 55150-0200-10
    • Ropivacaine injection, AuroMedics, 2 mg/mL, 100 mL infusion bottle, 25 count, NDC 55150-0196-99
    • Ropivacaine injection, Pfizer, 10 mg/mL, 10 mL vial, 10 count, NDC 00409-9303-10
    • Ropivacaine injection, Pfizer, 7.5 mg/mL, 20 mL vial, 10 count, NDC 00409-9302-20

Reason for the Shortage

    • Akorn had ropivacaine on shortage due to increased demand.
    • AuroMedics did not provide a reason for the shortage.
    • Fresenius Kabi has Naropin on shortage due to increased demand and manufacturing delays.
    • Pfizer had ropivacaine on shortage due to manufacturing delays.
    • Sagent has ropivacaine premixed bags available.
    • Somerset Therapeutics has ropivacaine 5 mg/mL 30 mL vials available.

Available Products

    • Naropin injection, Fresenius Kabi, 10 mg/mL, 10 mL Steripak plastic ampule, 5 count, NDC 63323-0288-10
    • Naropin injection, Fresenius Kabi, 10 mg/mL, 10 mL vial, 25 count, NDC 63323-0288-11
    • Naropin injection, Fresenius Kabi, 10 mg/mL, 20 mL Steripak plastic ampule, 5 count, NDC 63323-0288-20
    • Naropin injection, Fresenius Kabi, 10 mg/mL, 20 mL vial, 25 count, NDC 63323-0288-21
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 10 mL Steripak plastic ampule, 5 count, NDC 63323-0285-10
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 10 mL vial, 25 count, NDC 63323-0285-13
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 100 mL premixed bag, 1 count, NDC 63323-0285-61
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 20 mL Steripak plastic ampule, 5 count, NDC 63323-0285-20
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 20 mL vial, 25 count, NDC 63323-0285-23
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 200 mL premixed bag, 1 count, NDC 63323-0285-63
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 100 mL infusion bottle, 1 count, NDC 63323-0286-00
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 20 mL Steripak plastic ampule, 5 count, NDC 63323-0286-20
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 20 mL vial, 25 count, NDC 63323-0286-23
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 200 mL infusion bottle, 1 count, NDC 63323-0286-63
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 30 mL vial, 25 count, NDC 63323-0286-35
    • Naropin injection, Fresenius Kabi, 7.5 mg/mL, 20 mL Steripak plastic ampule, 5 count, NDC 63323-0287-20
    • Naropin injection, Fresenius Kabi, 7.5 mg/mL, 20 mL vial, 25 count, NDC 63323-0287-21
    • Ropivacaine injection, Akorn, 5 mg/mL, 30 mL vial, 1 count, NDC 17478-0081-30
    • Ropivacaine injection, AuroMedics, 10 mg/mL, 20 mL vial, 25 count, NDC 55150-0201-20
    • Ropivacaine injection, AuroMedics, 2 mg/mL, 20 mL vial, 25 count, NDC 55150-0195-20
    • Ropivacaine injection, AuroMedics, 5 mg/mL, 20 mL vial, 25 count, NDC 55150-0197-20
    • Ropivacaine injection, AuroMedics, 5 mg/mL, 30 mL vial, 25 count, NDC 55150-0198-30
    • Ropivacaine injection, AuroMedics, 7.5 mg/mL, 20 mL vial, 25 count, NDC 55150-0199-20
    • Ropivacaine injection, Pfizer, 10 mg/mL, 20 mL vial, 10 count, NDC 00409-9303-20
    • Ropivacaine injection, Pfizer, 2 mg/mL, 10 mL vial, 10 count, NDC 00409-9300-10
    • Ropivacaine injection, Pfizer, 2 mg/mL, 20 mL vial, 10 count, NDC 00409-9300-20
    • Ropivacaine injection, Pfizer, 5 mg/mL, 30 mL vial, 10 count, NDC 00409-9301-30
    • Ropivacaine injection, Sagent, 2 mg/mL, 100 mL premixed bag, 10 count, NDC 25021-0671-82
    • Ropivacaine injection, Sagent, 2 mg/mL, 200 mL premixed bag, 10 count, NDC 25021-0671-87
    • Ropivacaine injection, Sagent, 5 mg/mL, 100 mL premixed bag, 10 count, NDC 25021-0652-82
    • Ropivacaine injection, Sagent, 5 mg/mL, 200 mL premixed bag, 10 count, NDC 25021-0652-87
    • Ropivacaine injection, Somerset Therapeutics LLC, 5 mg/mL, 30 mL vial, 1 count, NDC 70069-0064-01

Estimated Resupply Dates

    • AuroMedics has ropivcaine 10 mg/mL 10 mL vials and 2 mg/mL 100 mL bottles on intermittent back order and the company is releasing product as it becomes available. There is a limited supply of short-dated 10 mg/mL 10 mL vials available.
    • Fresenius Kabi has Naropin 5 mg/mL 30 mL Steripak ampules on back order and the company cannot estimate a release date. The 2 mg/mL 100 mL bottles are on back order and the company estimates a release date of late-March 2020. The 2 mg/mL 200 mL bottles are on back order and the company estimates a release date of late-March 2020.
    • Pfizer has short-dated ropivacaine 7.5 mg/mL 20 mL vials available with an expiration date of April 2020. There are short-dated 10 mg/mL 10 mL vials available with an expiration date of June 2020.

Updated

Updated March 24, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 27, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.